The “RCT Augmentation”: A Novel Simulation Method to Add Patient Heterogeneity Into Phase III Trials

BMC Medical Research Methodology - United Kingdom
doi 10.1186/s12874-018-0534-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

A Phase Retrieval Method of Interferograms Add-Subtracting Based on Two-Step Phase Shifting

Bio-Medical Materials and Engineering
MedicineBiomaterialsBiomedical Engineering
2014English

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

Dermatology and Therapy
Dermatology
2017English

Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept

Clinical Cancer Research
Cancer ResearchOncology
2013English

Mutations in KLHL24 Add to the Molecular Heterogeneity of Epidermolysis Bullosa Simplex

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

Involving Patients in Optimising RCT Participant Information Sheets and Exploring Patient Acceptability of Clinical Trials

Trials
MedicinePharmacology
2013English

Practical Modifications to the Time-To-Event Continual Reassessment Method for Phase I Cancer Trials With Fast Patient Accrual and Late-Onset Toxicities

Statistics in Medicine
EpidemiologyStatisticsProbability
2011English

Simple Step Add-In to Improve Patient Safety: A Technical Note

Cureus
2020English

Strategies to Improve Response Rates to Patient Reported Outcome Measures in a Surgical RCT

Trials
MedicinePharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy